Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + metabolic cofactor supplementation
- Development stage
- Unknown
- Lead developer
- ScandiBio Therapeutics AB
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This investigational combination therapy, developed by ScandiBio Therapeutics AB, pairs the antimalarial drug hydroxychloroquine with a specific regimen of metabolic cofactors known as Combined Metabolic Cofactors Supplementation (CMCS). The CMCS component consists of four dietary supplements: N-acetylcysteine (NAC), L-carnitine tartrate, nicotinamide riboside, and L-serine. This combination is designed to act synergistically to support mitochondrial function, enhance NAD+ biosynthesis, and bolster antioxidant defenses through glutathione maintenance, thereby mitigating the metabolic stress and inflammatory response associated with COVID-19. In a Phase 2/3 clinical trial (NCT04573153), patients treated with this combination showed a significant reduction in recovery time compared to those receiving hydroxychloroquine alone.
- Other names
- Combined Metabolic Cofactors SupplementationCMCS + hydroxychloroquineMetabolic Cofactor Supplementation and Hydroxychloroquine Combination
02
Targets
TLR9 (Toll-like receptor 9)DNA
Beyond the preview
Go deeper on hydroxychloroquine + metabolic cofactor supplementation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + metabolic cofactor supplementation.